Ishami Mpuzamahanga

Ku ya 25 Mata 2025, InnoCare Pharma yatangaje ko icyorezo gishya cya pan-TRK inhibitor zurletrectinib (ICP-723) cyemejwe n'Ikigo gishinzwe Isuzuma ry'Imiti (CDE) cy'Ikigo cy'Igihugu cy'Ubushinwa gishinzwe Ibikoresho by'Ubuvuzi (NMPA), cyemeye Porogaramu Nshya y'Imiti (NDA) y'...Soma byinshi»

Ku itariki ya 25 Mata 2025, Innovent Biologics yatangaje ko Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi mu Bushinwa (NMPA) cyemeje Porogaramu Nshya y’Imiti (NDA) ya limertinib nk'uburyo bwa mbere bwo kuvura abarwayi bakuru bafite kanseri y’ibihaha idakomeye cyangwa isanzwe itera kanseri y’ibihaha (NSCLC) ...Soma byinshi»

Ku ya 23 Mata, penpulimab ya Akeso yemejwe n'Ikigo gishinzwe Ibiribwa n'Imiti hamwe na cisplatin cyangwa carboplatin na gemcitabine mu kuvura abantu bakuru bafite kanseri yo mu nda isubira cyangwa itera kanseri idatera keratinizing nasopharyngeal (NPC). FDA nayo yemeje penpulimab-kcqx nk'icyaha...Soma byinshi»

Ku ya 16 Werurwe 2025, Akeso yatangaje ko umuti wayo mushya wo kurwanya kanseri ya PD-1 monoclonal, penpulimab, wemejwe ku mugaragaro n'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) kugira ngo uvurwe kanseri yo mu nda isubira cyangwa ihinduka mu buryo buhuriweho ...Soma byinshi»

Ku ya 24 Mata 2025, GenFleet Therapeutics yatangaje ko Ikigo gishinzwe ibiribwa n'imiti muri Amerika (FDA) cyemeye gukoresha umuti mushya (IND) wa GFH375/VS-7375, umuti ubuza KRAS G12D (ON/OFF) mu kanwa, mu igeragezwa ry'ubuvuzi rivura abarwayi ba kanseri ikomeye bafite imihindagurikire ya KRAS G12D. Ubushakashatsi...Soma byinshi»

Ku ya 17 Mata 2025, Hansoh Pharmaceutical yatangaje ko umuti wa B7-H3-target antibody-drug conjugate (ADC) HS-20093 wikoreye itsinda wahawe uburenganzira bwo gushyirwa mu bwoko bwa Breakthrough-Therapy-Designed Medicine n’Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) cy’Ubushinwa, ...Soma byinshi»

Ku ya 15 Mata 2025, InnoCare Pharma yatangaje ko Ikigo gishinzwe gusuzuma imiti (CDE) cy’Ikigo cy’Igihugu cy’Ubushinwa gishinzwe imiti y’ubuvuzi (NMPA) cyemeye Porogaramu Nshya y’Imiti (NDA) yo mu bwoko bushya bw’umuti w’ingufu zurletrectinib (ICP-723) wo kuvura abantu bakuru n’ingimbi n’abangavu.Soma byinshi»

Vuba aha, GenFleet yatangaje amakuru aheruka y’icyiciro cya kabiri cy’ubushakashatsi bwa KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) hamwe na cetuximab mu kuvura kanseri y’ibihaha itari iy’uturemangingo duto (NSCLC), mu ncamake yasohotse mu kiganiro gito cyo mu 2025 cy’inama y’ubumwe bw’ibihugu by’i Burayi ya kanseri y’ibihaha...Soma byinshi»

PLB1004, yakozwe na Beijing Avistone Biotechnology Co., Ltd., ni umuti wizewe, utoranya cyane kandi ukora neza utuma tyrosine kinase inhibitor (EGFR-TKI) ikoreshwa mu kuvura kanseri y'ibihaha itari iy'uturemangingo duto (NSCLC). Ku ya 9 Mata 2025, Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi...Soma byinshi»

Ku ya 13 Werurwe 2025, ikinyamakuru mpuzamahanga gikomeye cyitwa Nature Medicine cyasohoye igerageza rya MediLink rya B7-H3 rigamije umuti uhuza abarwayi n’abarwanyi (ADC) YL201 Icyiciro cya 1/1b. Igerageza ryarimo igice cyo kongera igipimo (igice cya 1) n’igice cyo kongera igipimo (igice cya 1b). Abarwayi 312 bose hamwe banditswe muri ...Soma byinshi»

Ku ya 21 Werurwe 2025, Immunofoco yatangaje ko uburyo bwayo bwo kuvura bwa EpCAM-targeting autologous CAR-T cell therapy, IMC001, bwakozwe ku giti cyabwo, bwemerewe n'Ikigo gishinzwe gusuzuma imiti (CDE) munsi y'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) mu Bushinwa mu gikorwa cyayo cya kabiri cy'ubushakashatsi ku ndwara nshya ...Soma byinshi»

Ku ya 31 Werurwe 2025, Innovent Biologics yatangaje ko Ikigo gishinzwe gusuzuma imiti (CDE) cy’Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi mu Bushinwa (NMPA) cyemereye Itangwa ry’Ubuvuzi bwa Breakthrough (BTD) rya IBI363, poroteyine ya mbere mu cyiciro cya PD-1/IL-2α-bias bispecific antibody fusion, nk’uburyo bwo kuvura gusa...Soma byinshi»